NEWS OF THE W EEK
CHEMICAL SAFETY: Accidents reignite simmering tensions
T
WO SERIOUS ACCIDENTS occurred within two
days at the Map Ta Phut petrochemical production zone in eastern Thailand. An explosion on May 5 at a synthetic rubber plant owned by Bangkok Synthetics killed 12 people and injured more than 140 at Map Ta Phut. The next day, a chlorine leak at a hydrochloric acid plant operated by Aditya Birla Chemicals led to the hospitalization of 13 people, according to the Industrial Estate Authority of Thailand (IEAT). The back-to-back accidents have revived tensions between the facilities in the industrial zone and nearby residents who blame the petrochemical industry for causing pollution and posing a safety risk. Bangkok Synthetics said in a statement that the explosion occurred when the plant was shut down and undergoing maintenance. During a storm, a fire broke out in a toluene vessel that had just been cleaned, the company said. “As far as I can remember, this is the most serious accident to occur in the Thai petrochemical industry,” says Samuel Liew, associate director of Asian olefins and elastomers at the Singapore office of IHS Chemical, a market research firm. The death and injury toll was high, he says, because many contractors were at the site performing maintenance duties during the shutdown. Bangkok Synthetics is a key supplier of polybuta diene and styrene-butadiene rubbers to the welldeveloped Thai tire industry. The firm has “one of the smallest capacities in Asia, but a great influence on the market,” Liew says. The company has attracted loyal customers with its ability to deliver rubber reliably and
on schedule, Liew says. These customers will be struggling to secure supplies in coming months, with the result that rubber prices in Southeast Asia will be higher than elsewhere, Liew predicts. After the rubber plant explosion, Thai Prime Minister Yingluck Shinawatra ordered improvements in the warning systems that provide residents living near chemical facilities with evacuation information when an accident occurs. Two years ago, Thai residents opposed to the expansion of the chemical industry at Map Ta Phut succeeded in freezing the construction of all new projects at the industrial estate (C&EN, March 22, 2010, page 26). The two accidents have revived antagonism toward the petrochemical industry. Suthi Atchasai, the main activist behind the court case that resulted in the moratorium on further construction at Map Ta Phut, is preparing a new lawsuit to demand that buffer zones be created to separate local residents from the hazards of the chemical industry, the Thai news agency MCOT reports. At a meeting organized by IEAT on May 6, local residents expressed concerns about warning systems and evacuation procedures, the authority reported on its website. The government agency has promised to improve its disaster management procedures. The controversy is unlikely to affect a synthetic rubber plant being built at Map Ta Phut by a joint venture of Bangkok Synthetics and Japan’s JSR, Liew believes (C&EN, March 7, 2011, page 20). He notes that the venture has already obtained all the permits required by law.—JEAN-FRANÇOIS TREMBLAY ASSO CIAT ED P R ESS
EXPLOSION IN THAILAND KILLS 12
Thai Prime Minister Yingluck (center) visits an injured rubber plant worker in the hospital.
FRAUD Abbott Labs to pay $1.5 billion to resolve charges of off-label drug marketing Abbott Laboratories has agreed to pay a combined $1.5 billion to the U.S. govern ment and nearly all the states to settle charges that it illegally promoted the antiseizure drug Depakote for uses not approved by FDA. Among the charges by Justice De partment prosecutors was that Abbott promoted Depakote in nursing homes to control agitation and aggression in el derly patients with dementia and to treat schizophrenia. FDA had approved Depa kote only to control epileptic seizures and
bipolar mania and to prevent migraines. The settlement includes a criminal fine and forfeitures of $700 million to the U.S. government. It also includes payments of $561 million to the federal government and $239 million to state governments to settle charges of illegally billing health care programs such as Medicaid. In addi tion, Abbott agreed to plead guilty to one misdemeanor for misbranding Depakote under the Food, Drug & Cosmetic Act. James M. Cole, deputy U.S. attorney general, says the settlement shows the
WWW.CEN-ONLIN E .ORG
9
M AY 14, 20 1 2
Justice Department’s commitment “to hold accountable those who commit fraud.” Abbott’s general counsel, Laura J. Schumacher, says the firm was “pleased to resolve this matter” and has set up compliance programs per an agreement with the Justice Department to monitor marketing efforts. Other drug firms such as GlaxoSmith Kline and Pfizer have paid billions of dol lars to settle similar charges of fraudulent marketing.—MARC REISCH
